METHODS	A 12-week , multicenter , investigator-masked , randomized , parallel-group study was performed with more than 200 patients who were randomly assigned to regimens of tazarotene 0.1 % gel alone , tazarotene plus a high-potency topical corticosteroid ( fluocinonide 0.05 % ointment , mometasone furoate 0.1 % ointment , or diflorasone diacetate 0.05 % ointment ) , or tazarotene plus a mid-high-potency topical corticosteroid ( betamethasone dipropionate 0.05 % cream , fluticasone propionate 0.005 % ointment , or diflorasone diacetate 0.05 % cream ) .\